Please assess the completion status of the following clinical trial:

Trial Title: The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals of 18-70 years of age,~* with Type 2 Diabetes,~* with an HbA1c (6.5%-9%),~* and with a systolic blood pressure (120-160 mmHg).~Exclusion Criteria:~* Individuals with:~  1. Type 1 Diabetes,~ 2. eGFR \<50mL/min/1.73m,~ 3. pregnancy or breast feeding,~ 4. significant cardiac, pulmonary or liver disease,~ 5. prior history of pancreatitis, medullary thyroid cancer, multiple endocrine neoplasia syndromes,~ 6. SBP \>161 mmHg, 7) DBP \>100 mmHg,~ 7. alcohol or substance abuse,~ 8. states of secondary hypertension.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Experimental arm (Type: EXPERIMENTAL): sitagliptin (DPP-4 inhibitor) oral tablet (100 mg); Januvia; administered once daily for 28 days
- Placebo arm (Type: PLACEBO_COMPARATOR): placebo (no medicinal ingredients) oral tablet (100 mg); administered once daily for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).